Exploring the Potential of Receptor Silencing in the Tumor Microenvironment by RNA Interference
Biomolecules · 17.02.2026 · 16 (2) · 315
DOI: 10.3390/biom16020315 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 17.02.2026. Verfasst von Karina Mayumi Tani Bezerra de Melo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Avenida da Engenharia S/N, …. Hauptthemen laut MEDLINE: Tumor Microenvironment, RNA Interference, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Council for Scientific and Technological Development.
Abstract (Originalsprache)
Cancer is a heterogeneous disease caused by genetic and epigenetic factors, leading to alterations in signaling pathways and regulatory processes. Overall, the more commonly employed conventional treatments present side effects and resistance. Due to the diverse cellular composition of the tumor microenvironment, inhibition of cell communication by RNA interference (RNAi) has emerged as a strategy to regulate the expression of receptors linked to carcinogenesis. This review examines RNAi-mediated receptor silencing as a strategy to modify the tumor microenvironment, primarily in tumor cells, enhancing its vulnerability to immune cell destruction and reducing resistance to conventional therapies. In the tumor microenvironment, the silencing of immune checkpoints like PD-1 and CTLA-4 has demonstrated the ability to restore T cell function and enhance the efficacy of adoptive cell therapies. Additionally, the targeting of G protein-coupled receptors, including CXCR4, CCR5, and A2aR, as well as growth factor receptors such as VEGFR and EGFR, and interleukin receptors, interferes with pathways that are critical for tumor promotion, resulting in diminished angiogenesis, metastasis, and immunosuppression. These strategies utilize advanced delivery systems, including nanoparticles and exosomes, and show that silencing multiple targets can produce more effective antitumor outcomes than single-target methods, underscoring the significant potential of RNA interference in cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Avenida da Engenharia S/N, Recife 50740-600, Pernambuco, Brazil.
ORCID-Profile: Karina Mayumi Tani Bezerra de Melo, Beatriz Mendonça Alves Bandeira, Pedro Vinícius Silva Novis, Micaela Evellin Dos Santos Silva, Ingrid Andrêssa de Moura, Antonio Carlos de Freitas, Anna Jéssica Duarte Silva
Förderung
- National Council for Scientific and Technological Development
Zitieren
APA
Melo, K. M. T. B., Bandeira, B. M. A., Novis, P. V. S., Silva, M. E. D. S., Moura, I. A., Freitas, A. C., & Silva, A. J. D. (2026). Exploring the Potential of Receptor Silencing in the Tumor Microenvironment by RNA Interference. Biomolecules, 16(2), 315. https://doi.org/10.3390/biom16020315
Vancouver
Melo KMTB, Bandeira BMA, Novis PVS, Silva MEDS, Moura IA, Freitas AC, et al. Exploring the Potential of Receptor Silencing in the Tumor Microenvironment by RNA Interference. Biomolecules. 2026;16(2):315. doi:10.3390/biom16020315
BibTeX
@article{Melo2026,
author = {Melo, Karina Mayumi Tani Bezerra de and Bandeira, Beatriz Mendonça Alves and Novis, Pedro Vinícius Silva and Silva, Micaela Evellin Dos Santos and Moura, Ingrid Andrêssa de and Freitas, Antonio Carlos de and Silva, Anna Jéssica Duarte},
title = {Exploring the Potential of Receptor Silencing in the Tumor Microenvironment by RNA Interference},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {2},
pages = {315},
doi = {10.3390/biom16020315}
}
EUVIMED